Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 4 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1
4(100.0%)
4Total
Phase 1(4)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT04283097Phase 1Completed

Safety, Tolerability and Pharmacokinetics Study of KPG-818 in Hematological Malignancies Subjects

Role: lead

NCT04643067Phase 1Completed

Phase 1b/2a Study to Evaluate Safety and Efficacy of KPG-818 in SLE

Role: lead

NCT03569280Phase 1Completed

Evaluation of Safety and Efficacy of KPG-121 Plus Enzalutamide, Abiraterone or Apalutamide in CRPC Patients

Role: lead

NCT03949426Phase 1Completed

Safety, Tolerability and Pharmacokinetics of KPG-818 in Healthy Subjects

Role: lead

All 4 trials loaded